KRAS and small cell lung carcinoma: A dose-dependent inhibition of tumor growth was observed upon twice daily oral administration of BI-2493 in nude mice bearing tumors derived from the KRAS WT–amplified small cell lung cancer cell line DMS 53 (CN = 9.5; Fig. 4A).